Strategic IP Transfer Direct Diagnostics intellectual property has been transferred to OralDNA Labs as of September 1, 2024, presenting an opportunity for cross-selling of DNA-based diagnostics and leveraging OralDNA’s existing go-to-market channels and customer base.
Referral Marketing Expansion OralDNA Labs recently launched Referral Conduit software and hosts a Dental Referral Marketing Podcast, signaling a focus on partner-driven demand generation that could be complemented with additional diagnostic product integrations and channel partnerships.
Saliva Diagnostics Expertise Historical launch and FDA activity around salivary PCR and COVID-19 related tests indicate strong capabilities in non-invasive oral fluid testing, presenting upsell opportunities to dental and oral health practices seeking convenient, at-home or in-office testing options.
Scale and Partnerships Compared to larger lab networks, Direct Diagnostics/OralDNA appears lean with low current revenue; targeting cost-effective, scalable lab services partnerships with mid-market clinics and dental networks could yield rapid incremental revenue through contracted testing programs.
Platform and Tech Fit Tech stack commonality with cloud, communications, and marketing tools suggests receptivity to integrated solutions (LIS/connectivity, patient outreach, and CRM workflows) that streamline ordering, results delivery, and referral-based campaigns for dental and medical partners.